Table 4.

Factors Associated With Difference in ln(APRI), Among All HIV-Positive Participants^a

	Unadjusted		Adjusted
Factor	Fold Change in APRI (95% CI)	P Value	Fold Change in APRI (95% CI)	P Value
Hepatitis status
Uninfected	1		1
HBV or HCV infected	2.32 (1.95–2.76)	<.001	2.34 (1.97–2.79)	<.001
White race
No	0.86 (.75–.99)	.036	0.96 (.84–1.11)	.61
Yes	1		1
CD4 count ≤200 cells/mL
No	1		1
Yes	1.65 (1.43–1.9)	<.001	1.23 (1.03–1.47)	.022
Viral load ≥100000 copies/mL
No	1		1
Yes	1.37 (1.16–1.61)	<.001	1.26 (1.07–1.49)	.007
Current ART use
No therapy	1		1
Monotherapy	1.24 (1.04–1.47)	.015	0.93 (.77–1.11)	.396
Combination therapy	1.08 (.94–1.25)	.273	1.06 (.91–1.23)	.486
Current trimethoprim/sulfamethoxazole use
No	1		1
Yes	1.26 (1.09–1.47)	.002	0.95 (.80–1.13)	.542
Current fluconazole
No	1		1
Yes	1.76 (1.42–2.17)	<.001	1.21 (.95–1.54)	.118

Abbreviations: APRI, aspartate aminotransferase-to-platelet ratio index; ART, antiretroviral therapy; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus type 1; ln, natural logarithm.

^aModel also adjusts for age, heavy alcohol use, body mass index, and year of Multicenter AIDS Cohort Study visit.